SutroVax develops multivalent pneumococcal conjugate vaccines, including lead preclinical candidate SVX-24, a 24‑valent PCV designed to add 11 strains beyond Prevnar 13. Preclinical proof-of-concept studies showed comparable responses to the 13 common Prevnar 13 strains and superior responses to the 23 common Pneumovax®23 strains. The pipeline also includes SVX‑XP, a PCV with coverage of at least 30 strains intended as a future successor to SVX‑24. The company plans to use new funding to expand development efforts and advance its broad‑spectrum candidates into the clinic. Grant Pickering is CEO and Founder. The company is Foster City, Calif.-based and focuses on addressing emerging, antibiotic‑resistant, and high case‑fatality serotypes. SutroVax develops best-in-class conjugate and complex-antigen vaccines using Sutro Biopharma’s Xpress CF™ cell-free protein synthesis platform to enable site-specific conjugation and preserve critical B- and T-cell epitopes. The company exclusively licensed a conserved cell-wall polysaccharide antigen from the University of California, San Diego to pursue a universal Group A Streptococcus vaccine. The program targets broad protection against multiple Group A Strep strains while avoiding cross-reactive antibodies that could target human tissue. SutroVax is also pursuing a broader-spectrum pneumococcal conjugate vaccine among other programs. The company is based in Foster City, CA, and emphasizes higher-potency conjugates through precise and consistent antigen–protein conjugation. Financially, the company received non-dilutive development funding commitments to advance the Group A Strep program. SutroVax develops conjugate vaccines and novel complex antigen–based vaccines using exclusive rights to Sutro Biopharma’s Xpress CF™ cell-free protein synthesis platform. The platform enables precise, site-specific conjugation of antigens to protein carriers to preserve T-cell help and produce higher-potency conjugates. The company is using these conjugates to pursue a broader-spectrum pneumococcal conjugate vaccine (PCV) among other programs. SutroVax intends to advance its lead broad‑spectrum PCV candidate through mid‑stage clinical development and to expand its pipeline of novel vaccines. The company is led by CEO and founder Grant Pickering and is based in Foster City, California. The recent financing provides capital to support clinical progression and pipeline expansion. SutroVax is an independent vaccine platform and development company based in Foster City, CA, led by CEO Grant Pickering. The company develops conjugate vaccines and novel complex antigen-based vaccines using exclusive rights to the Xpress CF Platform, a cell-free protein synthesis technology. Its lead program is a broad-spectrum pneumococcal conjugate vaccine (PCV) designed to provide expanded protection against circulating strains of Streptococcus pneumoniae with potential to replace current infant and adult vaccines. SutroVax has generated preclinical proof-of-concept in head-to-head studies against current vaccines using well-accepted immunological endpoints. The company plans to use new funds to advance the lead PCV and accelerate antigen discovery and early-stage development in other disease areas. SutroVax completed a $22m Series A financing to advance its vaccine pipeline. The company will use the funds to advance multiple vaccines through pre-clinical proof of concept. Led by CEO Grant Pickering, SutroVax is developing vaccines for infectious disease targets with an initial emphasis on conjugate vaccines. It holds an exclusive license to Sutro Biopharma’s Xpress CF and Xpress CF+ platforms for cell free protein synthesis and site-specific conjugation. As part of the financing, Kurt von Emster of Abingworth will become interim Chairman and Patrick Enright and Dr. Tracy Saxton (from Longitude Capital and Roche Venture Fund, respectively) will join the board. The company is based in South San Francisco, CA.

Total raised

$292M

Funding rounds

5

Latest round

Series D

Latest activity

Mar 2020